history of glp-1 agonists A timeline of GLP- 1 discovery and clinical development. Created in GLP-1 Receptor Agonists – From

Effectiveness and Impact Significant Weight Loss: Phase 2 studies showed up to roughly 20% average body weight loss at 52 weeks in participants with obesity

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Retatrutide 10mg: Triple Receptor Agonist Research Compound

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials